The Lyme Disease Diagnostic Market is witnessing a surge in the adoption of molecular diagnostics, particularly Polymerase Chain Reaction (PCR) tests. These methods allow for the direct detection of Borrelia burgdorferi DNA in clinical samples, such as synovial fluid or skin biopsies, offering a more definitive diagnosis than indirect antibody tests. Technical specifications for molecular platforms are covered in the Lyme Disease Diagnostic Market research.

People also ask: Can PCR tests detect Lyme disease earlier than blood tests? What is the advantage of nucleic acid testing? PCR is especially valuable in diagnosing Lyme arthritis or early-stage disseminated disease where antibody levels may not yet be detectable.

New innovations like droplet digital PCR (ddPCR) are further enhancing sensitivity, allowing for the detection of even trace amounts of bacterial DNA. As these specialized tools become more cost-effective and standardized, they are expected to play a larger role in confirming chronic or persistent cases that are difficult to diagnose through conventional means.